About: Henry Seth Friedman

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Henry Seth Friedman Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

medical researcher

Attributes	Values
rdf:type	Item
description	medical researcher (en) медичний дослідник (uk)
rdfs:label	Henry Seth Friedman (en) Henry Seth Friedman (es) Henry Seth Friedman (nl) Henry Seth Friedman (sq)
skos:prefLabel	Henry Seth Friedman (en) Henry Seth Friedman (es) Henry Seth Friedman (nl) Henry Seth Friedman (sq)
name	Henry Seth Friedman (en) Henry Seth Friedman (es) Henry Seth Friedman (nl) Henry Seth Friedman (sq)
affiliation	wds:Q73422966-5f5a3a17-4c61-4bc9-5a4a-b9e6d8389228
affiliation	Duke University
given name	wds:Q73422966-19857E3E-6E07-4CFD-B4B8-8AA29BE9FAAF
given name	Henry
instance of	wds:Q73422966-13008bc7-4318-e895-f680-b992ab91074a
instance of	Homo sapiens
skos:altLabel	Henry Friedman (en) H. Friedman (en) H. S. Friedman (en) H.S. Friedman (en) HS Friedman (en) Henry S. Friedman (en)
occupation	wds:Q73422966-112b2589-4448-c315-7788-7507d57b343f
sex or gender	wds:Q73422966-D69C01BD-B23D-457A-BCCA-B8F1C6D67A14
official website	wds:Q73422966-e0c601b3-420e-ce15-e138-d6613b8be954
occupation	physician
sex or gender	male
official website	https://medicine.duke.edu/faculty/henry-seth-friedman-md
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73422966
is author of	IDH1 and IDH2 mutations in gliomas The genetic landscape of the childhood cancer medulloblastoma Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone and diaziquone-based drug combinations. Therapeutic profile of the human glioma line D-54 MG in athymic mice. Chromosomal composition of malignant human gliomas through serial subcutaneous transplantation in athymic mice. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy L-amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma. The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model. Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Hematologic toxicity during craniospinal irradiation: the impact of prior chemotherapy Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study Chemotherapy for adults with malignant glioma Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma Chromosomal characteristics of childhood brain tumors Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. Glioblastoma multiforme and the epidermal growth factor receptor Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme. Innovations in design and delivery of chemotherapy for brain tumors A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031) Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study Temozolomide and treatment of malignant glioma. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Identification of p53 as a sequence-specific DNA-binding protein Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. The genetic landscape of anaplastic astrocytoma Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas. Lack of efficacy of postoperative chemotherapy and delayed radiation in very young children with pineoblastoma. Pediatric Oncology Group Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR). Cyclophosphamide resistance in medulloblastoma. Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6 O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor An archival prospective study of mental health and longevity Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice Irinotecan: promising activity in the treatment of malignant glioma. Experience with irinotecan for the treatment of malignant glioma Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software